 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Cerus Corporation
 |
Cerus Corporation |
 |
 |
 |
NEWS FROM THE WIRES |
 |
Before The Bell - Dell, Ford hit; futures tumble further Aug 17 2001 05:51 AM PDT
Cerus, Baxter say blood systems meet primary goals Aug 17 2001 05:48 AM PDT
Cerus files shelf for sale up to $300 mln Aug 10 2001 01:15 PM PDT
> More WIRE STORIES about this company
PROFILE |
 |
Cerus is keeping it pure for the world. The firm develops blood-pathogen inactivation systems intended to purify donated blood and improve the safety of blood transfusions. The company's Intercept blood systems use proprietary small-molecule compounds to prevent pathogens, including HIV, hepatitis B and C viruses, and other bacteria and viruses, from replicating in blood products. Cerus is developing technology for use in bone-marrow transplants. The firm has a marketing and development agreement with medical instrument maker Baxter International, which owns more than 15% of Cerus.
COMPETITION |
 |
Cypress Bioscience, Inc. (CYPB)
V.I. Technologies, Inc. (VITX)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 1.90
1-Yr. Sales Growth: (20.8)%
Employees: 154
Revenue per employee: $12,337.66
KEY PEOPLE |
 |
Stephen T. Isaacs
CEO
Gregory W. Schafer
CFO
CONTACT INFO |
 |
2411 Stanwell Dr.
Concord, CA 94520
US
Phone: 925-288-6000
Fax: 925-603-9099
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |